产品说明书
Mexiletine HCl
 |
同义名 : | KOE-1173 hydrochloride;Mexiletine (hydrochloride);Ko 1173;Mexiletine hydrochloride |
| CAS号 : | 5370-01-4 | |
| 货号 : | A200751 | |
| 分子式 : | C11H18ClNO | |
| 纯度 : | 99% | |
| 分子量 : | 215.72 | |
| MDL号 : | MFCD00216024 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 40 mg/mL(185.43 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 100 mg/mL(463.56 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Mexiletine is an orally effective antiarrhythmic agent noted for its benefits in treating myotonia and neuropathic pain. It operates by inhibiting sodium channels, with an IC50 of 75±8 μM for tonic block and 23.6±2.8 μM for use-dependent block, making it relevant for both cardiovascular and neurological research[1].[2].[3].[4].[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02308748 | Drug-induced QT Prolongation ... 展开 >> Pharmacokinetics Pharmacodynamics 收起 << | Phase 1 | Completed | - | - |
| NCT02336477 | Non-dystrophic Myotonias ... 展开 >> Paramyotonia Congenita Myotonia Congenita 收起 << | Phase 3 | Completed | - | France ... 展开 >> Groupe Hospitalier Pitié Salpetriere Paris, France, 75013 收起 << |
| NCT02045667 | Non Dystrophic Myotonia | Phase 2 | Completed | - | Netherlands ... 展开 >> Departments of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands Nijmegen, Gelderland, Netherlands, 6500HB 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
4.64mL 0.93mL 0.46mL |
23.18mL 4.64mL 2.32mL |
46.36mL 9.27mL 4.64mL |
